SG11202001833WA - Improvements in igf-1 analysis, adjustment and disease management of non-neurological and/or neurological conditions - Google Patents

Improvements in igf-1 analysis, adjustment and disease management of non-neurological and/or neurological conditions

Info

Publication number
SG11202001833WA
SG11202001833WA SG11202001833WA SG11202001833WA SG11202001833WA SG 11202001833W A SG11202001833W A SG 11202001833WA SG 11202001833W A SG11202001833W A SG 11202001833WA SG 11202001833W A SG11202001833W A SG 11202001833WA SG 11202001833W A SG11202001833W A SG 11202001833WA
Authority
SG
Singapore
Prior art keywords
neurological
igf
analysis
adjustment
disease management
Prior art date
Application number
SG11202001833WA
Inventor
Jian Guan
Original Assignee
Vitality Wellness Nz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitality Wellness Nz Ltd filed Critical Vitality Wellness Nz Ltd
Publication of SG11202001833WA publication Critical patent/SG11202001833WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
SG11202001833WA 2017-08-28 2018-08-28 Improvements in igf-1 analysis, adjustment and disease management of non-neurological and/or neurological conditions SG11202001833WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ73500217 2017-08-28
NZ74231118 2018-05-07
PCT/NZ2018/050116 WO2019045575A1 (en) 2017-08-28 2018-08-28 Improvements in igf-1 analysis, adjustment and disease management of non-neurological and/or neurological conditions

Publications (1)

Publication Number Publication Date
SG11202001833WA true SG11202001833WA (en) 2020-03-30

Family

ID=65527747

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001833WA SG11202001833WA (en) 2017-08-28 2018-08-28 Improvements in igf-1 analysis, adjustment and disease management of non-neurological and/or neurological conditions

Country Status (8)

Country Link
US (1) US20210072240A1 (en)
EP (1) EP3675890A4 (en)
JP (2) JP7461880B2 (en)
CN (1) CN111278451A (en)
AU (1) AU2018323787A1 (en)
CA (1) CA3074193A1 (en)
SG (1) SG11202001833WA (en)
WO (1) WO2019045575A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6598412B1 (en) * 2019-06-04 2019-10-30 ゼライス株式会社 Food for improving cognitive function
KR20240121835A (en) * 2021-12-17 2024-08-09 더 씨쥐피 랩 리미티드 Animal, fungal and marine sources of cGP and increased concentrations of CGP for disease management and treatment of non-neurological and/or neurological conditions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6760M (en) * 1967-05-30 1969-03-03
US5262162A (en) * 1991-09-06 1993-11-16 Merz & Co. Gmbh & Co. Cerebral-activating extract
AU2002340465A1 (en) * 2001-11-09 2003-05-19 Neuronz Biosciences, Inc. Cyclo(prolyl-glycine) and methods of use to treat neural disorders
US7232798B2 (en) * 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
US20100247483A1 (en) * 2001-11-13 2010-09-30 Tran Loi H Therapeutic agent composition and method of use
EP1607006A1 (en) * 2004-06-18 2005-12-21 Unilever N.V. Functional berry composition
US8263069B2 (en) * 2008-12-31 2012-09-11 Johnson Lanny L Compositions including anthocyanin or anthocyanidin for the prevention or treatment of articular cartilage-associated conditions
JP2010202597A (en) 2009-03-04 2010-09-16 Kinki Univ Composition derived from plant of genus salacia, and method for producing the same composition
WO2012088100A2 (en) * 2010-12-21 2012-06-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Triclabendazole and fenbendazole for cell protection
RS60679B1 (en) * 2013-07-25 2020-09-30 Neuren Pharmaceuticals Ltd Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders
EP2899543A1 (en) 2014-01-28 2015-07-29 Predemtec GmbH Biomarker and methods for early diagnosis of Alzheimer's disease
EP3131418A1 (en) 2014-03-14 2017-02-22 New Chapter, Inc. Supplemental food
CN105087235A (en) * 2014-05-14 2015-11-25 王牌 Process for making healthcare liquor from blackcurrant and gynostemma pentaphyllum

Also Published As

Publication number Publication date
WO2019045575A1 (en) 2019-03-07
JP7461880B2 (en) 2024-04-04
JP2024012290A (en) 2024-01-30
EP3675890A4 (en) 2021-11-03
EP3675890A1 (en) 2020-07-08
JP2020532587A (en) 2020-11-12
AU2018323787A1 (en) 2020-04-09
US20210072240A1 (en) 2021-03-11
CA3074193A1 (en) 2019-03-07
CN111278451A (en) 2020-06-12

Similar Documents

Publication Publication Date Title
EP3531942A4 (en) Implant with curved bone contacting elements
HUE055334T2 (en) Organic compounds and their use in treating or preventing central nervous system disorders
HRP20210518T1 (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
PL3362449T3 (en) Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis
IL263188B (en) Treatment for parkinson's disease
HK1257935A1 (en) Aminoglycoside derivatives and uses thereof in treating genetic disorders
EP3677265A4 (en) Composition for preventing or treating sleep disorders
SG11202103972SA (en) Neurological disease treatment with zilucoplan
EP3558281A4 (en) Treatment of mental, movement and behavioral disorders
IL275349A (en) Use of hm4di in the treatment of seizure disorders
SG11202001833WA (en) Improvements in igf-1 analysis, adjustment and disease management of non-neurological and/or neurological conditions
IL271224A (en) Aminoglycoside derivatives and uses thereof in treating genetic disorders
EP3307775A4 (en) Methods for diagnosing and treating affective disorders
EP3256151A4 (en) Methods and compositions for treating muscle disease and disorders
GB201704429D0 (en) Calcitonin mimetics for treating diseases and disorders
IL279257A (en) Method of enhancing glucose levels in the central nervous system
IL274838A (en) Use of mir101 or mir128 in the treatment of seizure disorders
HRP20220490T8 (en) Thiazolidinone compounds and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation
ZA201807944B (en) Treatment for parkinson's disease
GB201711838D0 (en) Calcitonin mimetics for treating diseases and disorders
AU2017902338A0 (en) Sleep Disorder Composition and Treatment Thereof
GB201518052D0 (en) Parkinson's disease treatment
GB201704355D0 (en) Calcitonin mimetics for treating diseases and disorders
PT3148990T (en) Thiazolidinone compounds and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation